The aims of this study were to examine the relationships between CYP2D6 genotype and metoprolol dose, S-and R-metoprolol concentrations and clinical effects in patients with systolic heart failure. Data were obtained for 52 subjects, of which 27 had 2 functional alleles (24/27, CYP2D6*1/*1), 22 had 1 functional allele (18/22, CYP2D6*1/*4) and 3 had no functional alleles (CYP2D6*4/*4). Median dose-adjusted concentrations of S-metoprolol (active) were 6.3-and 3.2-fold higher in subjects with zero or one functional allele (P ¼ 0.016 and P ¼ 0.006), respectively, compared with subjects with two functional alleles. For the R-enantiomer (inactive), these concentrations were 10.7-and 3.7-fold higher (P ¼ 0.013 and P ¼ 0.003), respectively. Despite clear gene-concentration differences, no relationships between CYP2D6 genotype and dose or clinical effects could be shown. Although the number with no functional alleles was too small (n ¼ 3) to show effects, in patients with 1 functional allele other sources of variance are likely to be obscuring differences in clinical effects.
Introduction b-Adrenoceptor antagonists ('b-blockers'), particularly metoprolol, bisoprolol and carvedilol, have been shown to reduce morbidity and mortality in patients with systolic heart failure (HF). 1 However, recent work indicates that as few as 34% of patients with HF actually receive treatment with a b-blocker and up to 50% of these individuals may not achieve the target doses shown to be most effective in clinical trials. 2 There are likely to be many reasons for the low utilization of this class and the failure to achieve optimal doses in clinical practice. For individuals who respond to doses of b-blockers that are apparently suboptimal, there is evidence to suggest that lower doses may not necessarily lead to reduced effectiveness provided that the level of b-receptor antagonism is not compromised. 3 However, it is important to elucidate the mechanisms for variable response to ensure that patients are dosed appropriately.
Metoprolol, a lipophilic b 1 -adrenoceptor antagonist, is administered as a racemate, with the S-enantiomer producing most of the b-blockade. 4 The inactivation of metoprolol is considered to be mediated primarily through cytochrome P450 2D6 (CYP2D6), which is subject to genetic polymorphism. Early studies showed that patients who have no functional alleles of CYP2D6 (poor metabolisers (PMs)), who comprise approximately 7% of the Caucasian population, 5 achieve 3-to 6-fold higher concentrations of racemic metoprolol than extensive metabolisers (EMs) after a single-dose 6, 7 and with repeated dosing. [8] [9] [10] [11] Stereoselective metabolism exists, with the inactive R-enantiomer more dependent on CYP2D6 for metabolism, as indicated by an S/R concentration ratio of B1.1 and 1.7 in PMs versus EMs, respectively. 12 Additionally, studies in healthy volunteers indicate that PMs experience enhanced or prolonged b-blockade compared with EM subjects. 6, 13 Collectively, these findings suggest that elevated concentrations for a given dose in the PM group may explain the greater b-blockade observed.
Inferring CYP2D6 phenotype from genotype is complex as more than 70 alleles have so far been identified which alter CYP2D6 activity (http://www.cypalleles.ki.se/). Although the definition of PMs is fairly clear (two non-functional alleles), the guidelines in the literature are inconsistent regarding the definition of intermediate metabolisers (IMs) and EMs, especially for individuals with two alleles coding for reduced CYP2D6 activity. 14 To account for the range of activity encoded by different CYP2D6 alleles, activity scoring systems have been proposed. [14] [15] [16] Fully functional alleles (for example, CYP2D6*1) are assigned a value of 1, reduced activity alleles are assigned a value of either 0.5 (for example, CYP2D6*10) or 0.75 (for example, CYP2D6*9 and *41) and non-functional alleles (for example, CYP2D6*3, *4, *5 and *6) are assigned a value of 0. The activity score is obtained by adding together the activity values of the alleles carried by the individual.
In this study, we chose to subdivide the subjects into three genotype groups; individuals with two functional alleles (each with either fully or moderately reduced activity); individuals with only one functional allele; and individuals with no functional alleles (see Materials and methods and Results sections). We sought to investigate the relationship between CYP2D6 genotype and the maximum tolerated dose of metoprolol in patients with systolic HF. We also wanted to examine more explicitly the relationship between the CYP2D6 genotypes and steady-state concentrations of the S-and R-enantiomers of metoprolol. Secondary aims were to investigate the relationship between the CYP2D6 genotypes and end points of activity, including measures of b-blockade (heart rate and blood pressure) and disease control (left ventricular ejection fraction (LVEF), Nterminal pro-brain natriuretic peptide (NT-proBNP) concentration, and the New York Heart Association (NYHA) functional class) in patients on metoprolol. The principal hypothesis was that, in the clinical context, dose would be titrated in relation to benefit and/or adverse effect, and would reflect predicted CYP2D6 activity and concentrations of the active S-metoprolol. After appropriate dose-adjustment, clinical effects would be expected to be similar. It was hoped that a detailed study of the S-and R-enantiomers would improve our understanding of the relationships between the CYP2D6 genotype, concentrations of S-and R-metoprolol, clinical measures of b-blockade and disease control.
Results
Seventy patients agreed to participate in this study. Eight subjects (11%) were unable to continue metoprolol and are described separately below under 'patient withdrawals'. Eight other subjects were excluded; because an increase in metoprolol dose occurred subsequent to the study day, indicating that the maximum tolerated dose had not been reached (n ¼ 4); because of suspected noncompliance due to unmeasurable plasma concentrations of metoprolol (n ¼ 3); or because review of the clinical records identified diastolic rather than systolic HF (n ¼ 1). For two subjects genotype data could not be obtained. The remaining 52 subjects (37 male) had a mean (s.d.) age of 74 (9) years and weight of 79 kg (17) . Most of the individuals (48 of 52, that is, 92%) were self-defined as New Zealand European, whereas 4 (8%) were Maori or New Zealand European/ Maori. No subject had evidence of clinically important liver disease.
CYP2D6 genotype results for the 52 subjects revealed that 27 (52%) had two functional alleles, distributed into the following genotypes; CYP2D6*1/*1 (n ¼ 24), *1/*41 (n ¼ 2) and *1/*9 (n ¼ 1). With an activity score of 1 for CYP2D6*1 and 0.75 for the alleles with moderately reduced activity (CYP2D6*41 and CYP2D6*9), the combined activity score for this group was 1.75-2. Twenty-two (42%) subjects had one functional allele with the following genotypes: CYP2D6*1/*4 (n ¼ 18), *1/*3 (n ¼ 3) and *4/*41 (n ¼ 1), corresponding to the activity score of 0.75-1. The remaining three (6%) subjects had no functional alleles and were genotyped as CYP2D6 *4/*4 (n ¼ 3) with an activity score of 0. The CYP2D6*5, *6 and *10 alleles were not found in any individuals and no whole gene duplications were found. The allele frequencies observed in this study were consistent with those found in Caucasians in other studies. 17, 18 The mean age and weight, and ratio of males to females did not differ between the three genotype groups (data not shown).
The drugs taken in addition to metoprolol were fairly typical of those encountered in the HF setting and included ACE inhibitors/angiotensin II receptor antagonists (50 of 52 subjects, that is, 96%), loop diuretics (50, 96%), aspirin (38, 73%), HMG-CoA reductase inhibitors (33, 63%), warfarin (16, 31%), digoxin (17, 33%) and isosorbide mononitrate (17, 33%). The remaining drugs were taken by not more than 10 subjects each, and with the exception of CYP2D6 inhibitors and substrates were considered not likely to influence the outcomes of this study. Seven subjects (13%) took one of the strong CYP2D6 inhibitors, fluoxetine or paroxetine. A further 18 subjects (35%) took at least one drug known to be a substrate and/or weak inhibitor of CYP2D6 and comprised amiodarone (n ¼ 10), amitriptyline (n ¼ 3), codeine (n ¼ 4), perhexiline (n ¼ 2), dextropropoxyphene (n ¼ 3) or doxepin (n ¼ 1). Self-administered over-the-counter medications or herbal preparations were recorded, but few were being taken, and none were thought likely to influence metoprolol concentrations.
Metoprolol dose
All patients were administered a controlled release formulation of metoprolol. The median (interquartile (IQ) range) initial dose was 23.75 mg (23.75-47.5) daily. Eleven subjects (21%) were switched directly (reason unknown) from another b-blocker onto metoprolol and, as might be expected, had a higher median starting dose of 47.5 mg daily, compared with those with no prior b-blocker exposure whose median starting dose was 23.75 mg daily (P ¼ 0.016). There was no difference in starting dose between genotype groups (P ¼ 0.42; see Table 1 ).
The median (IQ range) maximum dose achieved overall was 95 mg day À1 (47.5-95), or 1.0 mg À1 kg À1 day À1 (0.5-1.4) after adjusting for body weight. The doses achieved for each of the individual genotype groups are shown in Table 1 . There were no significant differences in median dose achieved between the three groups. Only 7 of 52 participants (13%, three with two functional alleles and four with one functional allele) reached the recommended target dose of 190 mg day À1 . There was no difference in the maximum dose achieved between patients recruited from the two different HF clinics included in the study (P ¼ 0.26).
S-and R-metoprolol concentrations
Blood was sampled at a median (IQ range) of 6 h (4.2-9.5) post-dose, and the differences in time between genotype groups were not statistically significant (P ¼ 0.28).
The median (IQ range) concentration of S-metoprolol (the active enantiomer) was 8.6 mg l À1 (4.8-24) with a 130-fold range (0.7-90 mg l
À1
). As shown in Table 1 , S-metoprolol concentrations varied inversely with the number of functional CYP2D6 alleles (P ¼ 0.043). When concentrations were adjusted for dose, median concentrations were 3.2-fold (P ¼ 0.006) and 6.3-fold (P ¼ 0.016) higher in subjects with 1 or 0 functional allele, respectively, compared with subjects with 2 functional alleles (Table 1 and Figure 1 ).
The median (IQ range) concentration of R-metoprolol was 5.6 mg l À1 (2.4-20) and varied more than a 170-fold (range: 0.5-87 mg l À1 ). As seen for S-metoprolol, R-metoprolol concentrations varied inversely with number of functional CYP2D6 alleles (P ¼ 0.025). Dose-adjusted concentrations were 3.7-and 10.7-fold higher in subjects with one or zero functional allele compared with the subjects with two functional alleles (P ¼ 0.003 and P ¼ 0.013, respectively; Table 1 and Figure 1) .
The S/R concentration ratio (Table 1 and Figure 1 ) varied inversely with the three genotype groups, with median ratios of 1.6, 1.3 and B1.0 in individuals with two, one or zero functional allele, respectively (P ¼ 0.0008).
Other influences on S-and R-metoprolol concentrations Seven subjects (two with two functional alleles and five with one functional allele) were receiving concurrent treatment with the strong CYP2D6 inhibitors, fluoxetine (n ¼ 5) or paroxetine (n ¼ 2). The data points from these individuals are marked as filled circles in Figure 1 . As expected, we observed that individuals on these agents had significantly higher dose-adjusted concentrations of both S-and Table 1 Metoprolol dose and S-and R-metoprolol concentrations (median (IQ range)) versus CYP2D6 genotype Number of functional alleles 
28.6 (27.7-43.9)
per mg kg P ¼ 0.002
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CYP2D6, metoprolol and heart failure CF Sharp et al R-metoprolol (3-and 5-fold, respectively) than those who were not (P ¼ 0.001 and P ¼ 0.0003, respectively). The concentrations did not differ from those observed in the group with no functional alleles (P ¼ 0.52 and P ¼ 0.38, respectively), suggestive of phenocopying. Age (years) did not correlate with dose-adjusted S-metoprolol (r ¼ 0.14, P ¼ 0.33) or R-metoprolol (r ¼ 0.10, P ¼ 0.47) concentrations.
Clinical effects
Overall, treatment with metoprolol was associated with a significant reduction in heart rate (Po0.0001) and in systolic blood pressure (P ¼ 0.014), with median (IQ range) percent changes from baseline of À16% (À36 to À2.0%) and À5.8% (À18 to -3.8%), respectively. The median decrease in diastolic blood pressure of À7.7% (À21 to -14%) was not significant (P ¼ 0.14). There were no differences between genotype groups in the percent change from baseline in any of these measures (Table 2) .
Relevant data on the other clinical variables (NT-proBNP concentrations, LVEF and NYHA classes) were available for fewer subjects (n ¼ 22, 35 and 21, respectively) limiting the conclusions that can be drawn. Overall, NT-proBNP concentrations changed by À57% (À86 to À16%), which was a significant decrease from a baseline value of 357 (164-508) pmol l À1 to 177 (92-302) pmol l À1 (P ¼ 0.004, n ¼ 22). However, there was no difference between individuals with one or two functional alleles (P ¼ 0.72) as seen in Table 2 . Overall, the median (IQ range) LVEF was 36% (27-44%) at baseline and 41% (28-50%) after treatment with metoprolol (P ¼ 0.10, n ¼ 35). There was no difference between individuals with one or two functional alleles (P ¼ 0.52). For NYHA class, there was an improvement in class following metoprolol treatment in 12 out of 21 patients (P ¼ 0.003). There was no difference in the proportion of subjects with one or two functional alleles that improved with metoprolol treatment (7 of 12 versus 4 of 8, P ¼ 0.71).
Patient withdrawals
Eight individuals withdrew from the study because of side effects possibly related to metoprolol (three bronchospasm, two fatigue, one nightmares, one heart block and one unknown). These were genotyped for CYP2D6, but were not otherwise included in the results. These individuals had either one or two functional alleles (n ¼ 4 of each) and the proportion of patient withdrawals did not differ between genotype groups (P ¼ 0.79).
Discussion
In this study, the main aim was to determine whether CYP2D6 genotype correlated with the maximum tolerated dose of metoprolol achieved in patients with systolic HF. Other aims were to ascertain the relationships between CYP2D6 genotype and concentrations of S-and R-metoprolol, clinical measures of b-blockade and disease control in this patient group. At the time of the commencement of this study, published studies showed that healthy volunteers with no functional alleles (PMs) achieved 3-to 4-fold higher concentrations of racemic metoprolol and experienced enhanced b-blockade, compared with subjects with one or two functional alleles. 6, 8, 9, 13 Thus, we anticipated that in patients with HF, doses would be adjusted in relation to clinical indices and would correlate with predicted CYP2D6 activity and concentrations of the active S-metoprolol. Thus, after dose adjustment, clinical effects would be expected to be similar between groups.
This study design biased against showing clinical effects between genotype groups, if appropriate dose adjustments had been made. However, there was no statistically significant difference between CYP2D6 genoptype groups in the maximum tolerated dose of metoprolol achieved in patients with HF. However, exposure to the active S-metoprolol varied with predicted CYP2D6 activity such that individuals with one or zero functional alleles had doseadjusted concentrations that were 3-and 6-fold greater than achieved in individuals with two functional alleles, respectively. Despite these clear gene-concentration differences, no relationship between CYP2D6 genotype and clinical effects (blood pressure, heart rate, NYHA class, LVEF or NTproBNP) could be shown in this study. The number of subjects with no functional alleles (n ¼ 3) was too small for differences in clinical effects to be expected.
Since the commencement of our study, six prospective studies have been published in this field. This is interesting in itself, attesting to the current international interest in the topic, and enables a useful overall perspective. Only one other study was conducted in patients with HF as in this study. 19 Three of the studies were conducted primarily in individuals with hypertension, 15, 20, 21 one was in patients treated for acute myocardial infarct, 22 whereas one was a population-based study in which the indication was not mentioned. 23 Concentrations of the active S-enantiomer were measured in two of the studies 15, 19 and intergenotype differences in S-metoprolol concentrations were observed, although these were not as marked in extent as in our study.
In this study, subjects with one or zero functional allele had steady-state median dose-adjusted S-metoprolol concentrations that were 3-and 6-fold greater than subjects with two functional alleles, whereas Zineh et al.,
15 observed 1.3-and 3-fold higher mean area under the concentration-time curves (dose-adjusted), respectively, in their study of hypertensive patients on immediate release metoprolol. In a study of patients with HF receiving controlled release metoprolol by Terra et al., 19 individuals with one and two functional alleles were grouped together and found to have 3-fold higher median dose-adjusted S-metoprolol concentrations compared with individuals with no functional alleles. Application of the same genotype grouping to our data was also associated with a 3-fold difference. Thus, these studies and ours confirm that the metabolism of S-metoprolol is highly dependent on CYP2D6 activity, with concentrations varying inversely with predicted CYP2D6 activity. However, the differences seen in the two HF studies were greater than those observed in the hypertensive study, perhaps reflecting the different populations and metoprolol formulations studied.
R-metoprolol concentrations in our study were found to vary to a greater extent than S-metoprolol in relation to CYP2D6 activity, with individuals with one or zero functional allele having 4-and 11-fold higher dose-adjusted 
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À15 (À22 to -9.8) CYP2D6, metoprolol and heart failure CF Sharp et al concentrations, respectively, than those achieved in individuals with two functional alleles. The S/R metoprolol ratios were also found to vary between genotypes, at 1.6, 1.3 and 1.0 for two, one and zero functional alleles, respectively. These findings support the earlier observation in healthy volunteers of stereoselective metabolism of metoprolol, 24, 25 suggesting that R-metoprolol is more dependent on CYP2D6 for metabolism than S-metoprolol. In only one of the patient studies, 15 R-metoprolol concentrations were measured and these were not reported specifically. Consequently, we appear to be the first group to describe the relationship between CYP2D6 genotype and R-metoprolol concentrations in a patient group. The results confirm similar findings in healthy volunteers by Seeringer et al. 25 The differential influence of CYP2D6 activity on the R-and S-enantiomers has implications when racemic metoprolol concentrations are measured in therapeutic drug monitoring programs or in clinical studies. Concentrations of the active S-metoprolol are likely to correlate better with clinical effects. However, we have been unable to confirm this, since no difference in clinical effects (heart rate, blood pressure, NT-proBNP, LVEF or NYHA class) were found between the CYP2D6 groups in this study despite clear effects on S-metoprolol concentrations. This is consistent with some, 15, 19, 20, 26 but not all of the earlier patient studies. [21] [22] [23] 27 Three studies have now shown a correlation between CYP2D6 genotype and clinical effects of metoprolol. [21] [22] [23] Rau et al. 21 studied patients treated with extended release metoprolol primarily for hypertension and showed greater reductions in heart rate, diastolic blood pressure and mean arterial pressure in patients with no functional alleles (n ¼ 17) versus patients with one or two functional alleles (n ¼ 71). 21 These findings are supported by a populationbased study by Bijl et al., 23 who found that individuals with no functional alleles (n ¼ 34) had significantly lower heart rates and diastolic blood pressure compared with the wildtype (*1/*1) genotype (n ¼ 451). A further study in patients with acute myocardial infarct, showed higher mean heart rates in patients with greater CYP2D6 activity. 22 The main collective findings in these three studies were greater decreases in heart rate and diastolic blood pressure in patients with no functional alleles (true PMs). Unfortunately, in our study, we had insufficient patients with no functional alleles (n ¼ 3) for meaningful statistics to be carried out. Our study, therefore, is limited to examining for possible differences between patients with single functional allele (often termed as IMs) and those with two functional alleles (often termed as 'wild type'). We were unable to show differences in clinical effects despite clearly different concentrations of S-and R-metoprolol.
In the three studies mentioned above [21] [22] [23] that showed greater clinical effects in patients with no functional alleles, there was also some evidence of greater effects in patients with a single functional allele. Rau et al. 21 stated that although it was not a specific aim of the study, a significant trend for a greater decrease in heart rate and diastolic blood pressure was seen from EMs through IMs to PMs. In a study by Bijl et al., 23 a significant reduction in heart rate was seen in IMs (*1/*4) compared with EMs (*1/*1). In a study by Goryachkina et al., 22 the lowest heart rates were seen in PMs, and the highest in ultrarapid metabolisers (UMs). Collectively, these studies, which had larger numbers than our study, suggest that a genotype-effect relationship is likely in IMs, as in PMs.
Of the studies that did not show a correlation between CYP2D6 genotype and clinical effects, the study most similar to our own, Terra et al., 19 investigated the tolerability of controlled release metoprolol in 61 subjects with HF and observed no differences in rates of cardiac decompensation or dose achieved between genotype groups. The characteristics of the subjects appeared to be similar to our own with the exception of age, which was a mean of 57 years in the study of Terra et al. 19 , compared with 74 years in our study. 19 Zineh et al. 15 used a formal approach to dose titration of immediate release metoprolol in hypertensive patients. No differences in the rate of adverse events, dose achieved or change in blood pressure were observed between genotype groups. 15 Fux et al. 20 conducted an observational study with no formal approach to dose titration and investigated adverse effects in the first 6 weeks of metoprolol treatment (immediate or controlled release). No significant differences in blood pressure or heart rate between CYP2D6 genotype groups were observed, but a tendency toward more cold extremities (P ¼ 0.06) and a higher frequency of sexual dysfunction (Po0.05) were found in individuals with no or low CYP2D6 activity compared with those with greater CYP2D6 activity. 20 In addition to these prospective studies, two retrospective studies examined the relationship between CYP2D6 and adverse effects with metoprolol. 26, 27 In the first of these, Clark et al. 26 did not identify any difference in the sparteine (CYP2D6) phenotype distribution in 37 individuals who had stopped metoprolol due to adverse effects, or had increased antinuclear antibodies, compared with 37 age-and gendermatched controls. 26 In the second study, Wuttke et al.
27
found a disproportionately higher percentage (38%) of subjects with no functional alleles among 24 individuals with pronounced adverse effects to metoprolol (either b-blocker specific, for example, symptomatic bradycardia, or non-specific, for example, nausea) compared to that expected (7%). The disparate findings may reflect the different methodologies of the two studies. The former study identified subjects by systematic assessment of clinical notes at a hypertensive clinic, 26 while the second study invited physicians to recall patients who had pronounced side effects. 27 Many of the above studies, including our own, have involved small patient numbers, raising the possibility of type II error. This is supported by the fact that the larger studies were able to show significant differences in clinical effects between CYP2D6 genotypes, at least for PMs versus the other genotypes. It has been harder for all groups to show differences in clinical effects in patients with one functional allele compared with those with two functional alleles, despite clear evidence of differences in metoprolol concentrations. This suggests that sources of variance other than pharmacogenetic differences in CYP2D6-mediated metabolism are influencing clinical effects. Sources of variance in this study may include the complexity of the patient group studied, and the subjectiveness of the dose adjustments and some of the clinical assessments undertaken as part of routine care. For example, blood pressure and NYHA class were likely to be assessed by a number of clinicians and nurse specialists, introducing a substantial source of variability. Of the measures undertaken, plasma NT-proBNP concentrations probably offered the most objective assessment of ventricular function, 28, 29 but unfortunately observations were only available for about half of the subjects studied. In addition, our study design, in which doses were to be adjusted to clinical end points, thus normalizing clinical effects, could also dilute clinical signals.
Another source of variance that may obscure any genotype-effect relationship relates to the presence of other drugs that may result in phenocopying. In this study, we elected to include individuals on drugs that may influence metoprolol pharmacokinetics to reflect 'real life'. The class of greatest cause for concern in this respect consists of the selective serotonin reuptake inhibitors, fluoxetine and paroxetine, that strongly inhibit CYP2D6. We observed that individuals on these agents had significantly higher doseadjusted concentrations of both S-and R-metoprolol (3-and 5-fold, respectively) than those who were not, and that the concentrations did not differ from those observed in the group with no functional alleles. Paroxetine has been previously shown to increase exposure to both S-and R-metoprolol (5-and 8-fold, respectively) in a human study. 30 For fluoxetine, evidence from an in vitro study 31 and an earlier case report 32 is suggestive of a similar problem, but pharmacokinetic data in humans are lacking. Thus, this study provides evidence for a pharmacokinetic interaction between fluoxetine and metoprolol, and adds further evidence for a stereoselective disposition of metoprolol.
To clarify the influence of the interaction of fluoxetine and paroxetine on the conclusions drawn from this study, the entire data set was re-analysed without those seven individuals. As expected, the gene-concentration differences became more marked, whereas a relationship between CYP2D6 genotype and dose or clinical effects still could not be shown. This was not unexpected because of the reduced statistical power.
Given the many sources of variance and the interactions related to CYP2D6 inhibitors, it may be considered that S-metoprolol concentrations themselves may relate more directly to clinical end points than genotype. If a concentration-effect relationship was unable to be shown, then it would be too much to expect a genotype-effect relationship if such was solely a metabolic phenomenon. As noted in Table 2 , the clinical effect that changed most significantly with metoprolol treatment was heart rate. A plot of percentage decrease in heart rate versus S-metoprolol concentrations (Figure 2) showed that although the data points had wide scatter, many patients had a large effect at very low concentrations, suggesting early saturation of effect. These results are consistent with the concentrationeffect relationships shown by Seeringer et al. 25 which showed EC 50 values for decrease in heart rate of around 10-20 ng ml À1 . In the context of saturation at low concentrations, it is understandable that no clear metabolic genotype-effect relationship was demonstrable. In this regard, it is interesting to note that in the major two studies that showed clinical effects, dosages were relatively low, with concentrations within the ascending part of the concentration-effect curve.
It was perhaps surprising to see that only 13% (7 of 52) of the study participants achieved the target dose of 190 mg daily, but this seems to be a common finding. However, it compares unfavorably with the proportion of subjects in the MERIT-HF study (64%) who attained a comparable target dose (200 mg daily). 33 The reasons for the disparity are not clear, but it may relate in part to the different inclusion/exclusion criteria of the studies. For example, MERIT-HF avoided individuals on drugs, such as diltiazem or amiodarone that might influence metoprolol pharmacokinetics effect, whereas 10 (19%) of our participants took amiodarone and four (8%) took diltiazem. Our subjects also tended to be older (mean 74 years compared with 64 years in the MERIT-HF study). Thus, it is possible that the older age of our subjects, the presence of more co-morbidities and the prescription of some drugs that may influence metoprolol clearance or effect may have influenced the ability of our subjects to tolerate higher doses. In addition, it is expected that the target doses may be more aggressively pursued in the clinical trial setting than in routine care. Irrespective of these differences in study methodology, it is evident that only a small proportion (B13%) of individuals attending HF clinics in Canterbury, New Zealand, achieved the target doses of metoprolol. Attempts should be made to clarify the reasons for failure to achieve proven effective doses in clinical practice, or to establish why lower doses are adequate for some individuals.
Integrating our findings with those of others, we believe that for CYP2D6 and metoprolol, the following conclusions can be drawn. CYP2D6, metoprolol and heart failure 1. There is a dramatic gene dose-concentration effect between patients with zero, one or two functional CYP2D6 alleles. 2. There is a greater clinical effect (decrease in heart rate and diastolic blood pressure) in patients with no functional alleles. 3. There is a suggestion, in three studies with large patient numbers, of a greater decrease in heart rate in patients with one functional allele compared with patients with with functional alleles, but explained variance may be small compared with other sources. 4. There is a lack of effect on heart rate and diastolic blood pressure in ultrarapid metabolisers. 5. CYP2D6 is strongly involved in the metabolism of both Sand R-metoprolol, but the effect on R-is greater than on S-metoprolol. This has potential importance in the interpretation of racemic metoprolol concentrations. 6. For both R-and S-metoprolol, there is a reasonably clear concentration-effect relationship in terms of decreased heart rate, with an EC 50 of around 10-20 ng ml À1 . Saturation within concentrations related to standard dosing schedules may explain why it is difficult to show significant concentration-effect relationships in the case of single functional alleles.
Clinical implications
The studies in the literature showing increased clinical effects in patients with no functional alleles raises the possibility that screening of CYP2D6 before therapy to guide dosing might be useful. On the basis of area under the concentration-time curve (AUC), the starting dose should be decreased in patients with no functional alleles to around 20% of standard doses. However, the clinical reasons for doing this are not particularly compelling. Decrease in heart rate and diastolic blood pressure are both easy to measure clinically and allow easy dose titration. On the basis of current evidence, any dose reduction would only apply to patients with no functional alleles. However, prior knowledge of a single functional allele in a patient could also alert the physician to undertake more intensive monitoring, and perhaps exercise caution in pursuing higher doses.
To conclude, we have confirmed in patients with HF that S-and R-metoprolol concentrations at steady-state vary markedly according to CYP2D6 genotype, with the greatest effect seen in the inactive R-enantiomer. The differences in active S-metoprolol concentrations (dose-adjusted) between subjects with zero, one or two functional alleles were greater than observed in an earlier study of patients with hypertension. 15 In addition, we have provided more detailed results for the inter-genotype differences in plasma concentrations of the R-enantiomer than has been seen in other patient studies. 15, 19, 20 Despite the differences in exposure to S-metoprolol between CYP2D6 groups, no differences in metoprolol dose or clinical effects were seen between patients with single functional allele and those with two functional alleles. This may reflect the limited dose range used for metoprolol in HF, the subjective nature of adjusting dose and assessing some of the clinical effects (for example, NYHA class) and the complex underlying status (other diseases and other drugs) of the patients studied. It may also be simply a type II error, as a few studies with very large numbers do suggest discernable differences in clinical effects in these groups.
Materials and methods

Subjects and study design
Patients were eligible to participate if they had been titrated to their maximum tolerated dose of metoprolol for the treatment of systolic HF, and were attending one of the two HF clinics at Christchurch Hospital, Christchurch, New Zealand. Systolic HF was defined as LVEF p45% and NYHA classes II-IV. The maximum tolerated dose of metoprolol (Betaloc CR, Astra Zeneca, Auckland, New Zealand) was considered to be 190 mg controlled release (CR) daily based on clinical trial data, or a lower dose, if this target dose could not be reached, due to reasons such as symptomatic hypotension, bradycardia or dyspnea. When side effects necessitated a back titration of metoprolol dose, a second attempt at dose escalation was undertaken where possible after abatement of symptoms.
The first of the two HF clinics utilized as a source of patients for this study was the general outpatient HF clinic at Christchurch Hospital and the second was the clinic associated with the NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death ('BATTLE-SCARRED') trial. 34 Both clinics had the aim of optimizing the medical management of HF, including initiation and titration of b-blockers (metoprolol or carvedilol) in all patients unless contraindicated. The same guidelines for metoprolol dose titration were used in both HF clinics. The BATTLESCARRED trial aimed to determine whether drug treatment based on plasma NT-proBNP concentrations and intensive standardized clinical assessment improved outcomes compared with intensive standardized clinical assessment alone. 34 Most patients were expected to commence treatment with metoprolol CR at a dose of 23.75 mg daily, with the dose doubled at 2-4 weekly intervals. Contraindications to the use of metoprolol were typical of those expected for b-receptor antagonists and included bronchospastic airways disease, severe hypotension or bradycardia. For the purpose of this study, which aimed to reflect the 'real life' use of b-blockers for systolic HF, patients were excluded only if they had suspected or confirmed poor compliance with drug therapy or if their treatment was considered palliative, where aggressive pursuit of target doses was considered inappropriate.
Subjects underwent blood sampling for S-and R-metoprolol concentrations and CYP2D6 genotyping at least 4 h post-dose after at least 2 weeks on their maximum tolerated dose. Demographic and clinical information were sought from the subjects, their medical records and the HF clinic databases. Clinical information collected included blood pressure, heart rate and NYHA class before and after reaching the maximum tolerated dose, as well as plasma NT-proBNP concentrations and LVEF before and at least 6 months after commencing metoprolol treatment. Liver function tests were also used to identify those individuals with evidence of reduced ability to metabolize metoprolol (albumin o30 g l À1 , international normalized ratio 41.2 in the absence of warfarin).
Ethical approval was obtained from the Upper South B Regional Ethics Committee (New Zealand) and the written informed consent was obtained from all participants.
CYP2D6 genotyping DNA was obtained from 5 ml of whole blood using sodium chloride extraction. 35 Each subject was screened for four alleles associated with no CYP2D6 activity (CYP2D6*3, *4, *5 and *6), three alleles associated with reduced activity (*9, *10 and *41) and whole gene duplications (CYP2D6*nxn) using a two-step PCR assay. 36 Fully functional alleles (CYP2D6*1) were assigned a value of 1, moderately reduced activity alleles (CYP2D6*9 and *41) were assigned a value of 0.75 and nonfunctional alleles (CYP2D6*3, *4, *5 and *6) were assigned a value of 0. The activity score for each individual was then obtained by adding the activities of the individual alleles. The subjects were grouped as having either two functional alleles (activity score: 1.75-2), one functional allele (activity score: 0.75-1) or no functional alleles (activity score: 0).
S-and R-metoprolol concentrations
Blood samples (10 ml) were centrifuged at 2500 g for 10 min, following which the plasma was removed and stored at À80 1C until analysis. A chiral liquid chromatographytandem mass spectrometry assay was developed to measure S-and R-metoprolol concentrations in plasma. 37 A standard curve over the range of 0.5-50 mg l À1 was used, with samples containing 450 mg l À1 diluted with blank plasma. Each plasma sample was analyzed in triplicate. Quality control samples showed a precision of o10% relative s.d., and accuracy was within the range of 93-104% (86-105% at the limit of quantification of 0.5 mg l À1 ).
Statistical analyses
Continuous variables were described as median and IQ range and categorical variables were described using frequencies. Differences between groups were assessed using nonparametric tests; Mann-Whitney U-test, Kruskal-Wallis, or Wilcoxon-matched pairs t-test as appropriate, or w
